Dimensional Fund Advisors LP Sells 100,347 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Dimensional Fund Advisors LP trimmed its stake in CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 11.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 779,454 shares of the company’s stock after selling 100,347 shares during the period. Dimensional Fund Advisors LP owned approximately 0.98% of CRISPR Therapeutics worth $48,801,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CRSP. Signaturefd LLC lifted its stake in shares of CRISPR Therapeutics by 12.5% during the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock worth $96,000 after acquiring an additional 236 shares during the last quarter. Itau Unibanco Holding S.A. lifted its stake in shares of CRISPR Therapeutics by 10.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock worth $114,000 after acquiring an additional 245 shares during the last quarter. Spire Wealth Management lifted its stake in shares of CRISPR Therapeutics by 32.7% during the 3rd quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the last quarter. WealthPlan Investment Management LLC increased its holdings in CRISPR Therapeutics by 3.1% during the 4th quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock worth $605,000 after purchasing an additional 288 shares during the period. Finally, Merlin Capital Inc increased its holdings in CRISPR Therapeutics by 3.3% during the 3rd quarter. Merlin Capital Inc now owns 9,092 shares of the company’s stock worth $413,000 after purchasing an additional 290 shares during the period. 69.20% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on CRSP shares. Mizuho raised their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Oppenheimer reduced their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Wolfe Research started coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Needham & Company LLC reduced their price objective on CRISPR Therapeutics from $90.00 to $88.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, Citigroup cut their price target on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $73.57.

Check Out Our Latest Report on CRSP

Insider Activity

In related news, CEO Samarth Kulkarni sold 9,802 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $767,104.52. Following the completion of the transaction, the chief executive officer now owns 203,705 shares of the company’s stock, valued at approximately $15,941,953.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Samarth Kulkarni sold 9,802 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $767,104.52. Following the completion of the transaction, the chief executive officer now owns 203,705 shares of the company’s stock, valued at approximately $15,941,953.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the transaction, the general counsel now directly owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. Insiders sold a total of 55,709 shares of company stock valued at $3,865,228 in the last quarter. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Down 1.8 %

Shares of CRSP stock opened at $53.85 on Thursday. The stock has a market cap of $4.57 billion, a PE ratio of -19.80 and a beta of 1.80. The business has a 50-day simple moving average of $59.56 and a 200-day simple moving average of $65.70. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. The firm’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.67) earnings per share. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.64 earnings per share for the current fiscal year.

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.